News and Announcements
QHeart Medical – First Australian Private Company to Receive AISRF Support
- Published January 12, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- QHeart Medical (BioQ Devices Pty Ltd) only private research organisation to be awarded prestigious Australia India strategic research fund (AISRF) grant of $1Million.
- QHeart Medical participated in the Wholesale Investor Life Sciences event in Singapore to connect with Investors in the Asian region.
- QHeart Medical prepares for investment and showcases on the Wholesale Investor site.
- Winners of the QUT J&J Partnering Office pitch session (Dec 2017) with free entry into the 2018 MTPConnect BridgeTech Commercialisation program.
- World First Study: QHeart Medical successfully implanted their “pumpless” BioQ Cardiac Assist device using a minimally invasive procedure (MIS) on pigs QUT MERF, Brisbane (Dec 2017), avoiding open chest surgery and allow faster patient recovery.
QHeart Medical in collaboration with Frontier Lifeline Hospital, UNSW and QUT, are developing a revolutionary heart failure treatment device for heart failure which is highly unserved with cost effective and preventative treatment options and carries a massive economic burden to society. QHeart’s cost effective cardiac assist device, the BioQ CA, requires no pump or control system, and is designed to improve Quality of Life and reduce healthcare costs for millions of unserved patients worldwide. The Federal Government is supporting the program with the awarding of the prestigious Australia-India Strategic Fund (AISRF) grant.
In Oct’2017, QHeart Medical team presented at the Wholesale Investor Life Science event in Singapore to develop investor contacts.
In Dec’2017, QHeart Medical successfully placed the BioQ Cardiac Assist Device using minimally invasive procedure (MIS) on Pigs aorta at MERF, QUT, Brisbane. This will minimise the operating procedure time and assist faster patient recovery, and reduce treatment costs for this revolutionary affordable therapy.
In 2018, QHeart Medical is seeking further capital to accelerate the commercialisation activities of the BioQ CA heart failure treatment.
About QHeart Medical
QHeart Medical is commercialising a revolutionary heart failure treatment device for heart failure and hypertension which are highly unserved with cost-effective and preventative treatment options and carry a massive economic burden to society.
Our cost-effective self-powered cardiac assist device, the BioQ CA, requires no pump or control system, and aims to improve Quality of Life and reduce healthcare costs for millions of unserved patients worldwide.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
